Alamar Biosciences is a privately held life-sciences company focused on enabling the earliest detection of disease through precision proteomics. Its proprietary NULISA™ chemistry paired with the ARGO™ HT System delivers ultra-high sensitivity, addressing key limitations of existing protein-analysis technologies. The company positions its platform to unlock broad applications across health and disease, aiming to expand precision medicine and biomarker discovery. Recent capital infusions are being directed toward commercial advancement and scaling of this platform. Leadership additions—including Chief Scientific Officer Dr. Stephen Williams and two new board members—are intended to bolster scientific, operational, and financial execution. Headquartered in Fremont, California, Alamar continues to attract backing from top life-science and crossover investors. While revenue and user metrics are not disclosed, the company’s oversubscribed financings signal strong investor confidence in its growth prospects.

Total raised

$230M

Funding rounds

3

Latest round

Convertible Note

Latest activity

Jan 2026